News

Sarepta Therapeutics said it will resume shipments of its gene therapy Elevidys® (delandistrogene moxeparvovec-rokl) “imminently” to ambulant patients with Duchenne muscular dystrophy (DMD), ending a ...
The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.
The FDA has lifted its hold on Elevidys for ambulatory patients, after asking Sarepta to pause the treatment following three deaths.
Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, ...
Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would ...
The rAAVrh74 viral vector is a key component in several of Sarepta’s gene therapy programs, including Elevidys, an already FDA-approved gene therapy for Duchenne muscular dystrophy.
Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain patients while it evaluates new safety precautions.
In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy ...
A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the treatment The company plans to update prescribing information after ...
Sarepta says more than 800 patients have received the treatment The company plans to update prescribing information after this case WEDNESDAY, March 19, 2025 (HealthDay News) -- A patient has died ...
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.